Predictors of Influenza-Associated Absenteeism and Impact of Vaccination in a Cohort of Guatemalan Agricultural Workers
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3K23AI143967-01S1
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$49,756Funder
National Institutes of Health (NIH)Principal Investigator
DANIEL OLSONResearch Location
United States of AmericaLead Research Institution
UNIVERSITY OF COLORADO DENVERResearch Priority Alignment
N/A
Research Category
Epidemiological studies
Research Subcategory
Disease surveillance & mapping
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Farmers
Abstract
This is an Administrative Supplement Application to carry out SARS-CoV-2 PCR testing in an existing NIAID-funded study (1K23AI143967) evaluating the clinical and economic impacts of influenza in Guatemalanagricultural workers. The Parent Study includes the enrollment of an existing cohort (n=2,706) of Guatemalanagricultural workers with high rates of chronic medical conditions (CMCs) into a prospective active surveillancesystem for cough and fever (severe acute respiratory illness [SARI]). Workers meeting the case definition aretested for influenza A/B and RSV (Roche cobas® Liat RT-PCR Assay) and then clinical and economicoutcomes are assessed using follow up surveys and company reported absenteeism and productivity data. This Administrative Supplement will allow us to maintain our cough/fever surveillance system, given anincrease in expected cases due to SARS-CoV-2, and to perform RT-PCR testing for SARS-CoV-2. Wehypothesize that, similar to influenza, COVID-19 will place a significant clinical and economic burden onagricultural workers, especially the large proportion with CMCs, such as chronic kidney disease of unknownorigin (CKDu, aka "Mesoamerican nephropathy"), given existing data showing a significantly increased risk ofsevere disease. Evaluating these outcomes in an existing prospective cohort will allow us to measure theseburdens on a population-level, which will provide critical data in understanding the true impact of disease. Weaim to implement our SARS-CoV-2 testing immediately, analyze and disseminate our results quickly, andmake samples from our specimen biobank (annual blood and urine, acute illness respiratory and blood)available for additional research.